Highlights SinoMab BioScience Limited

Equities

3681

HK0000544194

Market Closed - Hong Kong S.E. Other stock markets 01:38:20 14/05/2024 pm IST			5-day change	1st Jan Change
1.82 ^HKD	+1.68%		-2.15%	+8.33%

25/03	SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
07/02	SinoMab BioScience Limited Appoints Shanchun Wang as an Executive Director	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2023	25/03	CI
SinoMab Bioscience Limited Announces First Cohort of the Health Subsidiaries Dosed in A Phase I Clinical Trial of SM17 in China	27/11	CI
China Accepts Clinical Trial Application for SinoMab BioScience's Alzheimer's Treatment; Shares Rise 3%	16/11	MT
Sinomab Bioscience Limited Announces IND Application for SM03 (Suciraslimab) for the Treatment of Alzheimer's Disease Accepted by NMPA CDE	15/11	CI
SinoMab BioScience Limited Announces National Medical Products Administration Accepts Biologics License Application for SM03 in the Treatment of Rheumatoid Arthritis	05/23/05	CI
SinoMab Bioscience to Shrink Loss in H1	22/23/22	MT
SinoMab BioScience Limited Reports Earnings Results for the Half Year Ended June 30, 2023	21/23/21	CI
Sinomab Bioscience Limited Announces IND Approval for Sm17 by Nmpa	14/23/14	CI
Sinomab Bioscience Limited Announces IND Application for SM17 Accepted by NMPA CDE	12/23/12	CI
Chinese Regulator Accepts SinoMab's Investigational New Drug Application for Asthma Treatment	22/23/22	MT
SinoMab BioScience Limited Announces Filing and Acceptance of Investigational New Drug Application for SM17 by the Center for Drug Evaluation of the National Medical Products Administration of China	22/23/22	CI
SinoMab BioScience Limited Announces Phase III Clinical Trial of its Product SM03 (Suciraslimab) Achieves the Primary Endpoint for Rheumatoid Arthritis	26/23/26	CI
SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2022	20/23/20	CI
Hainan Sinomab Enters into A Supplemental Lease Agreement with Haikou Pharma Pursuant to Which the Annual Rental of the Property	01/22/01	CI
SinoMab BioScience Targets $6.5 Million in Share Subscription Deal	03/22/03	MT
Sinomab Bioscience Limited Announces Enrollment in Phase I First-In-Human Clinical Trial	05/22/05	CI
Sinomab Bioscience Limited Announces IND Approval for SN1011 by National Medical Products Administration of China	23/22/23	CI
SinoMab BioScience's H1 Loss Widens; Shares Slip 5%	23/22/23	MT
SinoMab BioScience Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22/22/22	CI
SinoMab Bioscience Doses First Patient in US Clinical Trial of Asthma Drug	15/22/15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights SinoMab BioScience Limited

Equities

3681

HK0000544194

Highlights

Filters